The Lancet Neurology Publishes Clinical Results of PBT2 in Alzheimer’s Disease Patients

MELBOURNE, AUSTRALIA--(Marketwire - July 29, 2008) - Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, announced today the publication of the results of its Phase 2a clinical trial on Alzheimer's disease patients in The Lancet Neurology journal.
MORE ON THIS TOPIC